[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1997041916A1 - Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent - Google Patents

Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent Download PDF

Info

Publication number
WO1997041916A1
WO1997041916A1 PCT/US1997/007332 US9707332W WO9741916A1 WO 1997041916 A1 WO1997041916 A1 WO 1997041916A1 US 9707332 W US9707332 W US 9707332W WO 9741916 A1 WO9741916 A1 WO 9741916A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
stent
agent
delivering
vessel
Prior art date
Application number
PCT/US1997/007332
Other languages
English (en)
Inventor
J. Edward Shapland
Robert G. Walsh
Jan Ellen Fowler
Original Assignee
Emed Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emed Corporation filed Critical Emed Corporation
Priority to JP9540018A priority Critical patent/JP2000509623A/ja
Priority to EP97922585A priority patent/EP0959933A1/fr
Priority to AU28215/97A priority patent/AU2821597A/en
Publication of WO1997041916A1 publication Critical patent/WO1997041916A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2/958—Inflatable balloons for placing stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes

Definitions

  • the present invention relates to the treatment of cardiovascular ailments, and more particularly to combined coronary stent deployment and local delivery of an agent .
  • Angioplasty is commonly used to treat stenosis, which is a narrowing or stricture in a blood vessel.
  • Stenosis is usually caused by a buildup of plaque or raised patches along the inner lining of an artery.
  • Plaque can consist of fats, oils, decaying muscle cells, fibrous tissue, clumps of blood platelets, cholesterol, and calcium.
  • a buildup is called a stenotic lesion and usually occurs in a coronary or peripheral artery.
  • a balloon is inserted into the artery and positioned at the site of the stenotic lesion. The balloon is then inflated, which dilates the lumen in the artery and compresses and/or cracks the stenotic lesion.
  • This action increases the size of the lumen formed by the vessel and improves blood flow.
  • One problem with angioplasty is that there is a high rate of restenosis following the procedure, which is a renarrowing or reclosure of the vessel. In fact, about 30%-50% of patients receiving angioplasty experience restenosis within six months from the date that the procedure is performed.
  • Another complication from angioplasty is an abrupt reclosure of the vessel, which may be caused by a tear or rupture in the vessel wall. Such trauma can cause a flap that falls into the lumen of the vessel and impedes blood flow.
  • One technique to prevent reclosure of the blood vessel due to maladies such as tears, ruptures, and elastic recoil of the vessel wall after angioplasty is to place an intravascular stent at the site of the tear, rupture, or original stenosis.
  • the angioplasty catheter is initially inserted at the site of the stenotic lesion and expanded in order to expand the vessel and compress the lesion.
  • the angioplasty balloon is removed and a second, balloon-type catheter is inserted and carries the stent to the site of the tear, rupture, or original stenotic lesion.
  • the balloon of the second catheter is inflated to expand the stent against the vessel wall.
  • other types of catheters could be used in lieu of a balloon-type catheter.
  • the second catheter is removed after the stent is positioned.
  • a third balloon-type catheter is introduced into the vessel and its balloon positioned within the stent.
  • the balloon is then inflated to high pressures in order to over expand the stent. Ensuring that the stent is fully expanded in this manner can reduce the rate of restenosis.
  • the stent acts as a semi-rigid structure that maintains the vessel in an open state.
  • a difficulty with this procedure is that it requires the insertion and removal of multiple catheters in order to perform the entire procedure, which increases the chances of complications and undue trauma to the patient. For example, there is an increased risk of tears or damage to the vessel wall. There is further risk because using three separate catheters requires an increased amount of time to complete the surgical procedure.
  • stents do not prevent renarrowing due to maladies such as cell proliferation or the formation of a thrombus.
  • Cell proliferation is the formation of scar tissue and can be caused from the presence of a foreign object within the body, a mismatch in the compliance between the stent and the vessel wall, or the healing of tears in the vessel wall.
  • a thrombus is a blood clot that can be caused from turbulence in the blood flow that is induced by the stent.
  • Cell proliferation and the formation of a thrombus can be prevented with a therapeutic agent.
  • Cell proliferation can be prevented with an agent such as an antiproliferative agent, and a thrombosis can be prevented with an agent such as an anticoagulant.
  • Such drugs typically are delivered systematically and thus carried throughout the vascular system.
  • systemic delivery can be harmful because the agent is exposed to healthy tissue as well as diseased tissue.
  • systemic delivery can introduce unwanted side effects. For example, maintaining a high systemic level of an antiproliferative agent can cause unwanted cellular toxicity in healthy cells, and a high systemic level of an anticoagulant can cause internal bleeding or excessive bleeding at wounds such as the puncture wound required to permit catheter access.
  • Local delivery of a therapeutic agent at the treatment area is a possible alternative to systemic delivery.
  • the difficulty is that local delivery of the agent requires the introduction of yet another catheter that is specifically designed for drug delivery. Introducing a fourth catheter is not desirable because it will increase the risk of causing further trauma and side effects to the patient. It will also dramatically increase the expense of the procedure.
  • the present invention fills this need by providing an apparatus and method that delivers an agent, positions a stent, and expands a stent with a single catheter.
  • the same catheter can also be used to perform angioplasty.
  • the apparatus comprises a catheter defining a lumen and a balloon in fluid communication with the lumen.
  • the balloon defines pores sized about 1 ⁇ or less.
  • a stent is mounted on the balloon.
  • the present invention is also directed to an apparatus for delivering a stent to a treatment area that comprises a catheter defining a lumen.
  • a balloon is in fluid communication with the lumen, and a stent is mounted on the balloon.
  • the stent is formed with an electrically conductive material.
  • a lead extends along the catheter. The lead has one end in electrical communication with the electrode and an opposite end configured to be connected to a power supply.
  • a catheter defines a lumen.
  • a balloon is in fluid communication with the lumen, and a stent is mounted on the balloon.
  • the balloon defines pores sized about 1 ⁇ or less.
  • the stent is formed from a biodegradable material or coated with a biodegradable material. The biodegradable material is configured to retain the agent and slowly release the agent .
  • the present invention is also directed to a method of delivering a stent to a vessel using a catheter having a balloon and a stent that extends around the balloon.
  • the method comprises the steps of: positioning the balloon in the vessel so that the balloon and stent are proximate a treatment area; delivering a therapeutic agent to the treatment area while the balloon is proximate the treatment area; and inflating the balloon so that the stent expands against the vessel wall .
  • An alternative embodiment comprises the steps of: positioning the balloon and the stent in the vessel so that the balloon and stent are proximate a treatment area; delivering a therapeutic agent to the treatment area while the balloon is proximate the treatment area; and inflating the balloon thereby simultaneously expanding the stent against the vessel wall and performing angioplasty.
  • Yet another alternative embodiment includes the steps of positioning the balloon and the stent in the vessel so that the balloon and stent are proximate a treatment area; and inflating the balloon with a therapeutic agent thereby simultaneously expanding the stent against the vessel wall, performing angioplasty, and delivering the therapeutic agent.
  • Still another embodiment of the present invention is directed to a method of performing angioplasty and delivering a stent to a vessel using a catheter having a balloon.
  • the method comprises the steps of : performing angioplasty wherein the balloon is positioned in the vessel so that the balloon is proximate a treatment area, is inflated, and is removed from the vessel; and then deploying the stent wherein a stent is mounted on the balloon, the balloon is repositioned proximate the treatment area, and is inflated so that the stent expands against the vessel wall.
  • Figure 1 illustrates a catheter of the present invention in which a stent is mounted on a microporous balloon
  • Figure 2 shows the catheter of Figure 1 and illustrates the microporous balloon in an inflated state and the stent in an expanded state;
  • Figure 3 shows the catheter of Figure 2 taken along line 3-3 and illustrates an electrode positioned within a chamber defined by the microporous balloon;
  • Figure 4 illustrates an alternative embodiment of catheter shown in Figure 3 in which a surface of the microporous balloon is coated with an agent-retaining material
  • Figure 5 illustrates another alternative embodiment of the catheter shown in Figure 3 in which the surface of the stent is coated with an agent- retaining material .
  • the present invention relates to a catheter that can carry a stent, position the stent at a target area, fully expand the stent, and locally deliver an agent.
  • a caregiver introduces the catheter into the patient's vessel and positions the stent at a treatment area.
  • the caregiver can then expand the stent and locally deliver an agent .
  • the treatment area can include a stenotic lesion and surrounding tissue, a tear in the vessel, or a rupture in the vessel.
  • This apparatus and method has several significant advantages. For example, insertion of the stent, expansion of the stent, and local delivery of the agent are performed with a single catheter. The caregiver does not have to introduce and withdraw multiple catheters in order to perform this procedure.
  • the amount of time required to complete the procedure is also reduced. Accordingly, the cost of the procedure, the amount of trauma, and the risk of complications are also reduced. Furthermore, local delivery of the agent can permit maintenance of a therapeutic level of the agent while minimizing exposure of the agent to otherwise healthy tissue. The risk of causing side effects such as excessive bleeding is also reduced.
  • An agent can be any type of substance that is used for medical purposes and can be in a fluid form such as a solution.
  • agents include, but are not limited to, drugs, antiproliferative agents, anticoagulants, genetic material, biological agents, and radioactive substances such as isotopes. Radioactive substances are helpful because they kill cells in the treatment area and prevent cell proliferation.
  • An agent also can be a single agent or a combination of different agents.
  • catheter as used in the present application is intended to broadly include, but is not limited to, any medical device designed for insertion into a body passageway that can be used for both the deployment of a stent and delivery of an agent.
  • a catheter 10 includes a catheter body 11 and a balloon 12 that forms a microporous membrane.
  • the membrane can have pores sized from about 10 A to about 1 ⁇ , and a pore density from about IO 4 to about 10 11 pores per cm . Pores sized at or below about 150 A are small enough to minimize the flow of fluid through the pores, but is still large enough to permit the pores to be wetted and electric current to flow through the pores and carry the agent.
  • a catheter having such a balloon is described in more detail in commonly assigned United States application serial number 08/376,765, filed on January 23, 1995 and entitled
  • MICROPOROUS CATHETER MICROPOROUS CATHETER
  • a stent 14 is mounted on the balloon 12.
  • the length of the stent 14 is slightly less than the length of the balloon 12. In this configuration, the entire length of the stent 14 will expand upon inflation of the balloon 12.
  • the stent is a tube 16 that defines a plurality of slits 18.
  • the stent 14 can be formed from biodegradable materials or metals . Examples of metals include, but are not limited to, stainless steel, nitinol, and tantalum.
  • the stent 14 can have other designs such as a coil spring, helical coil, tubular wire mesh, or any other type of stent that can be expanded by the balloon 12.
  • Figure 2 illustrates the microporous balloon 12 and stent 14 in expanded states.
  • the stent 14 When the stent 14 is in an expanded state, the slits 18 are widened, thereby providing the stent with an increased circumference. Additionally, the stent 14 is semi-rigid in this state and will both comply with and maintain the expanded vessel wall in an open state.
  • the balloon 12 defines a chamber 13 and has impermeable end caps 15 and 17. Impermeable end caps are described in more detail in commonly-assigned United States Patent 5,232,444, which is entitled Dilation Catheter, the disclosure of which is hereby incorporated by reference.
  • the catheter 10 includes an inflation lumen 20, a coil-wire electrode 22 and a lead 24.
  • the coil-wire electrode 22 is positioned in the chamber 13 and is wrapped around the catheter body 11.
  • the lead 24 is in electrical communication with the coil-wire electrode 22 and extends through the lumen 20 so that it can be connected to a power supply (not shown) .
  • a patch-type electrode (not shown) is configured to be placed against the patient's skin and is also connected to the power supply.
  • catheter 10 can have a bi-polar electrode arrangement. Bi-polar electrode arrangements are discussed in more detail in commonly-assigned United States Application serial number 08/291,394, filed on August 16, 1994 and entitled POLYMER MATRIX DRUG DELIVERY APPARATUS AND METHOD, the disclosure of which is hereby incorporated by reference.
  • a caregiver will identify a treatment area where the stent 14 is to be located.
  • the treatment area can be a site where a lesion is located, a site where angioplasty was performed, a site where a venous or synthetic vascular graft was inserted into a vessel, a site where a tear or rupture was caused in a vessel, or any other portion of a vessel that requires support .
  • the treatment area is typically, but not necessarily, located in a coronary or peripheral artery.
  • the caregiver will introduce the catheter 10 into the vessel and position the stent 14 so that it is within the treatment area.
  • the caregiver will then inject agent through the lumen 20 and into the chamber 13.
  • the agent is pressurized from about 1 atm to about 10 atm, which wets the pores in the balloon 12, provides a path for electrical current to flow between the coil- wire electrode 22 and the patch-type electrode, and provides an initial expansion of the stent 14.
  • the power source is then activated and the agent is iontophoretically transferred from the chamber 13 to tissue surrounding the balloon 12.
  • phonophoresis also can be used to transport the agent from the balloon 12 to the target area. If phonophoresis is used, the coil-wire electrode 22 is replaced with an ultrasonic transducer, and there is no patch-type electrode. Iontophoresis and phonophoresis are described in more detail in commonly-assigned United States Patent 5,286,254, which is entitled Microporous Membrane and the disclosure of which is hereby incorporated by reference. After the agent is delivered, the caregiver will increase the pressure of the agent within the chamber 13, which will cause the balloon 12 to further inflate and fully or over expand the stent 14.
  • the caregiver wants greater control over the dose of agent that is delivered, he/she can withdraw the agent from the chamber 13 after delivery is completed and then inflate the balloon with a non-therapeutic substance such as sterile saline in order to expand the stent.
  • a non-therapeutic substance such as sterile saline
  • the stent is fully or over expanded when the stent 14 firmly presses against or becomes embedded in the vessel wall. In this state, the stent and vessel wall should conform with one another.
  • the level to which the pressure of the agent is increased depends on the diameter of the vessel in which the stent 14 is placed and on how much the caregiver desires to expand the circumference of the stent 14. The larger the circumference that is desired, the greater the pressure that must be applied to the agent.
  • the level to which the pressure of the agent is increased in order to fully or over expand the stent is typically between about 4 atm and about 20 atm. Such pressures ensure that all areas of the stent 14 become expanded and firmly press against the vessel wall. After the stent 14 is expanded, the balloon 12 is deflated and the catheter 10 is withdrawn from the patient.
  • the caregiver can continue to transport the agent while the stent is being expanded.
  • the caregiver can also continue to transport agent after the sent is expanded.
  • the stent could be expanded prior to delivery of the agent.
  • the stent 14 can be heated or cooled in order to cause it to expand if nitinol metal is used to form the stent 14.
  • Nitinol metal has a memory. When nitinol metal is heated or cooled from an original temperature to a selected memory temperature and reshaped from a first shape to a second shape, its memory is set so that the metal will return to the first shape when it is reheated or recooled to the selected memory temperature. In use, the nitinol metal is heated or cooled to the selected memory temperature in order to expand the stent 14.
  • the stent 14 could be warmed by heating or cooling the agent that is injected into the balloon 12 or by injecting a heated or cooled fluid into the balloon 12 either before or after the agent is injected into the balloon 12.
  • the selected memory temperature can be set at body temperature in which case the stent 14 will maintain its expanded shape. If the memory temperature is set at body temperature, the caregiver can rely on body heat generated by the patient to expand the stent. The caregiver could also artificially heat the metal to body temperature.
  • a nitinol stent that is already deployed in a vessel can be repositioned or removed by positioning a catheter balloon in the stent and then either heating or cooling the stent to its original temperature so that it shrinks and becomes remounted on the balloon. If the stent is being repositioned, the catheter can be moved to the new location and the stent can then be allowed to cool or warm to the first memory temperature and reexpand. If the stent is being removed, the catheter simply can be removed from the patients body.
  • the catheter 10 it is also possible to use the catheter 10 to perform angioplasty. If the catheter 10 is used to perform angioplasty, the caregiver can simultaneously perform angioplasty, deliver the agent, and expand the stent. Simultaneous angioplasty and delivery of the agent is discussed in more detail in commonly-assigned United States Patent
  • the caregiver could also use the catheter 10 to perform angioplasty and deliver an agent, withdraw the catheter 10, mount the stent 14 on the catheter 10, reintroduce the catheter to deploy the stent 14, and deliver additional agent.
  • This alternative method is advantageous because the caregiver can use the microporous balloon 12 to simultaneously deliver a first drug such as an antiproliferative agent during angioplasty and to simultaneously deliver a second agent such as an anticoagulant during stent deployment.
  • a first drug such as an antiproliferative agent during angioplasty
  • a second agent such as an anticoagulant during stent deployment.
  • There is additional advantage because only a single catheter 10 is needed to perform angioplasty, deliver the agents, and deploy the stent 14. As a result, there is a cost savings because less medical equipment is needed. Furthermore, the medical procedure can be performed much more efficiently because the amount of equipment that the caregiver must handle is reduced.
  • Pressure can also be used as the primary transport mechanism for delivering the agent. If pressure is the primary transport mechanism, one skilled in the art will recognize that catheter 10 does not need to include the electrode 22 and the lead 24.
  • the caregiver pressurizes the agent within the balloon 12 to a first predetermined level, which will cause the agent to flow through pores defined in the balloon.
  • the first predetermined level is between about 1 atm and about 10 atm.
  • the caregiver increases the pressure of the agent to a second predetermined level, which will cause the balloon 12 to expand and thus cause the stent 14 to expand.
  • the second predetermined level is between about 4 atm and about 20 atm.
  • the pore size and density can be set so that: (1) only a minimal amount of agent will flow through the pores at the first predetermined pressure level; and (2) the prescribed dose of agent will wet and flow through the pores at the second predetermined level. Controlling the pore size in this manner is described in more detail in commonly- assigned United States Patent 5,458,568, which is entitled Selectively Permeable Membrane for Drug Delivery Catheter, the disclosure of which is hereby incorporated by reference.
  • the prescribed dose of agent is delivered at the first predetermined level, the agent is withdrawn from the balloon 12 and a second, non- therapeutic fluid is injected into the balloon 12 to expand the stent 14. Pressure also can be used in conjunction with iontophoretic or phonophoretic delivery.
  • an alternative embodiment includes an agent-retaining coating 26 on the outer surface of the balloon, which can be impregnated with the agent.
  • the coating can be any suitable material that can retain the agent such as a polymer matrix or an open-cell foam.
  • the agent-retaining coating 26 can be formed from either a compressible or a non-compressible material.
  • a non-compressible material is advantageous because non-compressible material will minimize any loss of the agent as the catheter 10 is maneuvered through the vessel and prematurely becomes compressed against the vessel wall.
  • Polymer matrixes as an agent-retaining reservoir is described in more detail in commonly-assigned United States patent application serial number 08/291,394, the disclosure of which was incorporated by reference above.
  • the balloon 12 is dipped into a supply of agent in order to load the agent-retaining coating 26 before the catheter 10 is introduced into the vessel.
  • the caregiver can then follow the treatment steps as described above.
  • the balloon 12 can be inflated with any type of fluid, such as sterile saline, that will provide a conductive path between the coil-wire electrode 22 and the agent-retaining coating 26.
  • the inflation fluid can also contain additional agent or a different type of agent.
  • the agent-retaining material 26 can be loaded after the balloon 12 and stent 14 are positioned at the treatment area. After the balloon 12 is positioned, the agent is injected into the chamber 13 via the lumen 20. The agent is then slightly pressurized between about 2 atm to about 3 atm, which will cause some agent to flow through the pores and saturate the agent- retaining material. If this alternative method is used, the pores have a size greater than about 150 A. Additionally, the agent-retaining material can be swellable and compressible. In an alternative embodiment to the configuration shown in Figure 4, a metallic coating (not shown) can be used in place of the coil-wire electrode 22. The metallic coating can be positioned between the outer surface of the balloon 12 and the agent-retaining coating 26.
  • the balloon 12 can be formed from an impermeable material.
  • the metallic coating can be applied to the inner surface of the balloon 12, in which case the balloon 12 is porous in order to provide electrical communication between the electrode and the agent-retaining coating 26.
  • no electrode is present.
  • the balloon 12 can be impermeable, and pressure is the primary mechanism for delivering agent from the agent-retaining coating 26.
  • the agent-retaining coating 26 is preloaded before the catheter 10 is introduced into the vessel .
  • another alternative embodiment of the present invention includes an agent- retaining coating 28 applied to the outer surface of the stent 14.
  • the coating can be formed from either a biodegradable material or a non-biodegradable material .
  • the coating 28 is designed to reduce premature diffusion of the agent .
  • One technique for reducing premature diffusion of the agent is to entrap the agent within the coating 28. Release or diffusion of the agent then can be limited to allowing the coating 28 to degrade or to phoretically transporting the agent using a mechanism such as iontophoresis or phonophoresis.
  • the coating 28 can be a polymer matrix. Nevertheless, one skilled in the art will realize that the coating can have a number of other physical structures.
  • a strip 30 extends along the length of the balloon 12.
  • the strip 30 is formed from an electrically conductive material and provides electrical communication between the lead 24 and the stent 14.
  • the strip 30 can separate from the stent 14 upon deflation of the balloon 12. In this configuration, the catheter can be removed from the patient and the stent 14 can be left behind, i.e., positioned in the vessel.
  • the balloon 12 can be coated with a metallic material.
  • the stent 14 also is formed from an electrically conductive material and the lead 24 is operably connected to the strip 30.
  • the lead 24 extends down through the catheter body 11 and extends through the lumen 20. In this configuration, the stent 14 acts as an electrode.
  • FIG. 5 The embodiment shown in Figure 5 is used in a manner that is substantially similar to the steps described above.
  • an electrical current passes between the stent 14 and the patch-type electrode that is affixed to the patient's body.
  • the electrical current will transport the agent from the agent-retaining coating 28 to tissue surrounding the stent 14.
  • the balloon 12 can be inflated with an agent, which would permit simultaneous transport of an agent from the chamber 13 of the balloon 12 and from the agent-retaining coating 28.
  • the agent used to inflate the balloon 12 could be the same agent that is included in the agent-retaining coating 28 or could be a different agent than the agent included in the agent- retaining coating 28.
  • the balloon 12 can be formed from an impermeable material and can be inflated with any suitable fluid.
  • the agent-retaining coating 28 can be formed from a biodegradable material .
  • the agent-retaining coating 28 will gradually degrade after the stent 14 is positioned in the vessel and the catheter 10 is removed. This embodiment is advantageous because a therapeutic level of the agent can be maintained at the treatment area for an extended period of time after the catheter is removed.
  • This embodiment might be used for the sustained release of an anticoagulant such as an antithrombotic agent in order to prevent formation of a thrombus. If the agent-retaining coating 28 is biodegradable, iontophoresis or phonophoresis could still be used to transport the agent. Alternatively, the agent can be delivered by simply placing the stent 14 in the vessel.
  • the catheter 10 does not need to include an active transport mechanism such as an electrode or an ultrasonic transducer.
  • the balloon 12 can be formed from an impermeable material.
  • the agent- retaining coating 28 is formed from biodegradable material and the agent included in the coating 28 has a neutral charge, there could be both immediate delivery of an agent and sustained delivery of an agent. Immediate delivery could occur by delivering the agent that is injected into the chamber 13 by use of iontophoresis, phonophoresis, or pressure. If iontophoresis is used, the strip 30 can be replaced with the coil-wire electrode 22. If phonophoresis is used, the strip 30 is replace with an ultrasonic transducer.
  • Sustained release of the agent could occur by allowing the agent-retaining coating 28 to degrade thereby releasing the agent that is included within the coating 28.
  • This alternative delivery is advantageous when delivering both an anticoagulant and an agent such as an antiproliferative agent or radioactive isotope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Electrotherapy Devices (AREA)

Abstract

La présente invention concerne la mise en place d'un extenseur dans un vaisseau à l'aide d'un cathéter doté d'un ballonnet sur lequel est monté un extenseur. L'extenseur est positionné à l'aide d'un cathéter, il est écarté à l'aide du même cathéter et un agent thérapeutique est délivré également à l'aide du cathéter.
PCT/US1997/007332 1996-05-03 1997-05-02 Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent WO1997041916A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9540018A JP2000509623A (ja) 1996-05-03 1997-05-02 冠状動脈のステントの配置と薬剤の部分的投与の組み合わせ
EP97922585A EP0959933A1 (fr) 1996-05-03 1997-05-02 Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent
AU28215/97A AU2821597A (en) 1996-05-03 1997-05-02 Combined coronary stent deployment and local delivery of an agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64253696A 1996-05-03 1996-05-03
US08/642,536 1996-05-03

Publications (1)

Publication Number Publication Date
WO1997041916A1 true WO1997041916A1 (fr) 1997-11-13

Family

ID=24576997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/007332 WO1997041916A1 (fr) 1996-05-03 1997-05-02 Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent

Country Status (4)

Country Link
EP (1) EP0959933A1 (fr)
JP (1) JP2000509623A (fr)
AU (1) AU2821597A (fr)
WO (1) WO1997041916A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032267A3 (fr) * 1998-12-03 2000-11-23 Scimed Life Systems Inc Apport local de medicaments a efficacite elevee
US6196230B1 (en) 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
US6302892B1 (en) 1999-08-04 2001-10-16 Percardia, Inc. Blood flow conduit delivery system and method of use
EP1112724A3 (fr) * 1999-12-22 2002-06-12 Ethicon, Inc. Stent amovible pour lumières corporelles
WO2003022179A3 (fr) * 2001-09-07 2003-12-04 Jan Otto Solem Appareil et procede de mise en place d'un dispositif medical auto-expansible
US6981987B2 (en) 1999-12-22 2006-01-03 Ethicon, Inc. Removable stent for body lumens
WO2006047191A1 (fr) * 2004-10-21 2006-05-04 Boston Scientific Limited Implant medical a densite de charge de surface moyenne
US7163562B2 (en) 1999-12-22 2007-01-16 Ethicon, Inc. Biodegradable stent
US7169187B2 (en) 1999-12-22 2007-01-30 Ethicon, Inc. Biodegradable stent
EP1901796A2 (fr) * 2005-07-08 2008-03-26 C.R.Bard, Inc. Systeme de delivrance de medicaments
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
EP2331187A1 (fr) * 2008-09-02 2011-06-15 By-Pass, Inc. Cathéter à ballonnet microporeux
WO2011081712A1 (fr) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Délivrance de médicament activée par cryothérapie et ballonnets de coupe
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9066990B2 (en) 2001-03-26 2015-06-30 Bayer Intellectual Property Gmbh Preparation for restenosis prevention
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US9216273B2 (en) 2002-09-20 2015-12-22 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
CN111110415A (zh) * 2020-03-10 2020-05-08 上海星伙医疗科技有限公司 一种带球囊辅助扩张的前列腺支架输送系统
US12059544B2 (en) * 2016-10-20 2024-08-13 Asahi Medical Technologies, Inc. Method and device for enhanced composition delivery

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1521603T3 (da) * 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
US20050033263A1 (en) * 2003-08-07 2005-02-10 Medtronic-Minimed, Inc. System and method for restenosis mitigation
US20060216431A1 (en) * 2005-03-28 2006-09-28 Kerrigan Cameron K Electrostatic abluminal coating of a stent crimped on a balloon catheter
EP2789354A1 (fr) * 2013-04-13 2014-10-15 IPPyramids GmbH Ballonnet de cathéter pourvu de microperçages et d'un réseau métallique
JP2022536885A (ja) * 2019-04-08 2022-08-22 パテル、ウダヤン バイパス通路を備えたカテーテル上の膨張可能バルーン

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364787A1 (fr) * 1988-10-04 1990-04-25 EXPANDABLE GRAFTS PARTNERSHIP a Texas General Partnership Greffe extensible intraluminaire
US5213576A (en) * 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5236413A (en) * 1990-05-07 1993-08-17 Feiring Andrew J Method and apparatus for inducing the permeation of medication into internal tissue
US5254089A (en) * 1992-04-02 1993-10-19 Boston Scientific Corp. Medication dispensing balloon catheter
WO1993025265A1 (fr) * 1992-06-12 1993-12-23 Mallinckrodt Medical, Inc. Catheter gonflable a double fonction de dilatation et de perfusion
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5364356A (en) * 1993-07-19 1994-11-15 Bavaria Medizin Technologie Gmbh Sleeve catheter
WO1996011720A1 (fr) * 1994-10-17 1996-04-25 Kabushikikaisha Igaki Iryo Sekkei Extenseur endovasculaire liberant un medicament

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364787A1 (fr) * 1988-10-04 1990-04-25 EXPANDABLE GRAFTS PARTNERSHIP a Texas General Partnership Greffe extensible intraluminaire
US5236413A (en) * 1990-05-07 1993-08-17 Feiring Andrew J Method and apparatus for inducing the permeation of medication into internal tissue
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5213576A (en) * 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5254089A (en) * 1992-04-02 1993-10-19 Boston Scientific Corp. Medication dispensing balloon catheter
WO1993025265A1 (fr) * 1992-06-12 1993-12-23 Mallinckrodt Medical, Inc. Catheter gonflable a double fonction de dilatation et de perfusion
US5364356A (en) * 1993-07-19 1994-11-15 Bavaria Medizin Technologie Gmbh Sleeve catheter
WO1996011720A1 (fr) * 1994-10-17 1996-04-25 Kabushikikaisha Igaki Iryo Sekkei Extenseur endovasculaire liberant un medicament

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US6369039B1 (en) 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US6196230B1 (en) 1998-09-10 2001-03-06 Percardia, Inc. Stent delivery system and method of use
WO2000032267A3 (fr) * 1998-12-03 2000-11-23 Scimed Life Systems Inc Apport local de medicaments a efficacite elevee
JP2003521275A (ja) * 1998-12-03 2003-07-15 ボストン サイエンティフィック リミテッド 高能率局所薬物送達
US6302892B1 (en) 1999-08-04 2001-10-16 Percardia, Inc. Blood flow conduit delivery system and method of use
US7163562B2 (en) 1999-12-22 2007-01-16 Ethicon, Inc. Biodegradable stent
US6981987B2 (en) 1999-12-22 2006-01-03 Ethicon, Inc. Removable stent for body lumens
EP1112724A3 (fr) * 1999-12-22 2002-06-12 Ethicon, Inc. Stent amovible pour lumières corporelles
US7166134B2 (en) 1999-12-22 2007-01-23 Ethicon, Inc. Biodegradable stent
US7169187B2 (en) 1999-12-22 2007-01-30 Ethicon, Inc. Biodegradable stent
US9066990B2 (en) 2001-03-26 2015-06-30 Bayer Intellectual Property Gmbh Preparation for restenosis prevention
WO2003022179A3 (fr) * 2001-09-07 2003-12-04 Jan Otto Solem Appareil et procede de mise en place d'un dispositif medical auto-expansible
US9216273B2 (en) 2002-09-20 2015-12-22 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US9687635B2 (en) 2002-09-20 2017-06-27 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US9302080B2 (en) 2002-09-20 2016-04-05 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
US9216272B2 (en) 2002-09-20 2015-12-22 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments
WO2006047191A1 (fr) * 2004-10-21 2006-05-04 Boston Scientific Limited Implant medical a densite de charge de surface moyenne
EP1901796A2 (fr) * 2005-07-08 2008-03-26 C.R.Bard, Inc. Systeme de delivrance de medicaments
EP1901796A4 (fr) * 2005-07-08 2011-01-05 Bard Inc C R Systeme de delivrance de medicaments
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US9284409B2 (en) 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8221822B2 (en) 2007-07-31 2012-07-17 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
US8900292B2 (en) 2007-08-03 2014-12-02 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8920491B2 (en) 2008-04-22 2014-12-30 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
EP2331187A4 (fr) * 2008-09-02 2011-09-28 By Pass Inc Cathéter à ballonnet microporeux
EP2331187A1 (fr) * 2008-09-02 2011-06-15 By-Pass, Inc. Cathéter à ballonnet microporeux
US11278648B2 (en) 2009-07-10 2022-03-22 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
US10369256B2 (en) 2009-07-10 2019-08-06 Boston Scientific Scimed, Inc. Use of nanocrystals for drug delivery from a balloon
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
WO2011081712A1 (fr) * 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Délivrance de médicament activée par cryothérapie et ballonnets de coupe
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US12059544B2 (en) * 2016-10-20 2024-08-13 Asahi Medical Technologies, Inc. Method and device for enhanced composition delivery
CN111110415A (zh) * 2020-03-10 2020-05-08 上海星伙医疗科技有限公司 一种带球囊辅助扩张的前列腺支架输送系统

Also Published As

Publication number Publication date
JP2000509623A (ja) 2000-08-02
EP0959933A1 (fr) 1999-12-01
AU2821597A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
WO1997041916A1 (fr) Mise en place d'un extenseur coronarien combinee avec un apport local d'un agent
US5807306A (en) Polymer matrix drug delivery apparatus
US8162880B2 (en) Delivery of therapeutic and marking substance through intra lumen expansion of a delivery device
JP2940859B2 (ja) 脈管内ステント用形状記憶ロック機構
US5180366A (en) Apparatus and method for angioplasty and for preventing re-stenosis
JP3372950B2 (ja) ドラッグデリバリーシステム
US6340368B1 (en) Implantable device with radiopaque ends
JP3372250B2 (ja) 内部組織薬剤浸透装置
US5851171A (en) Catheter assembly for centering a radiation source within a body lumen
JP4436761B2 (ja) 薬剤放出用拡張性ポーションを備えた装置
US6991617B2 (en) Vascular treatment method and device
US5910101A (en) Device for loading and centering a vascular radiation therapy source
US5256141A (en) Biological material deployment method and apparatus
US20040106952A1 (en) Treating arrhythmias by altering properties of tissue
WO1995018649A1 (fr) Dispositif de stimulation cardiaque et d'administration locale de medicament simultanees
EP0805705A1 (fr) Procede d'administration d'un agent a un organe
WO2005007229A2 (fr) Separateur temporaire pour tissus et ballonnet de pre-traitement
US20230381468A1 (en) Inflatable balloon over catheter with bypass passageway
US11826089B2 (en) Compression stent device and methods
JP2002502677A (ja) 血液灌流能力を有する放射線供給カテーテル
WO1999040962A1 (fr) Catheter de centrage de rayonnement avec capacite d'irrigation sanguine
CN117224281A (zh) 一种促进药物吸收的血管支架

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997922585

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1997922585

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997922585

Country of ref document: EP